Read more
This volume provides case histories illustrating the types of interdisciplinary interactions necessary to design drug candidates with optimal pharmacological, pharmaceutical, biopharmaceutical, and metabolic/pharmacokinetic properties.
Key features include an incisive discussion of HIV protease inhibitors and 287 illustrations.
List of contents
Introduction; R. Hirschmann. Renin Inhibitors; S.H. Rosenberg, H.D. Kleinert. The Discovery and Development of Angiotensin II Antagonists; D.J. Carini, et al. Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor; R.T. Shuman, P.D. Gesellchen. Discovery and Development of an Endothelin-A Receptor Selective Antagonist PD 156707; A.M. Doherty, A.C.G. Uprichard. Endothelin Receptor Antagonists; J.D. Elliott, et al. LHRH Antagonists; F. Haviv, et al. LHRH Agonists; K.W. Funk, et al. Discovery and Development of Somatostatin Agonists; P. Marbach, et al. Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors;; G.E. Padbury, et al. The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development: The Story of Crixivan®, an HIV Protease Inhibitor; J.H. Lin, et al. De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule; G.V. De Lucca, et al. Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delaviridine Mesylate; W.J. Adams, et al. 12 Additional Chapters. Index.
